Focal Segmental Glomerulosclerosis Fsgs clinical trials

Explore recruiting focal segmental glomerulosclerosis fsgs clinical trials.

Recruiting focal segmental glomerulosclerosis fsgs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Focal Segmental Glomerulosclerosis Fsgs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Germany, Belgium, France, Spain, Czechia, Croatia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

France, Portugal, Spain, Slovakia, Italy, Germany +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)

Poland, Germany, Sweden, Netherlands, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

France, Spain, Denmark, Germany, Italy, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Germany, Croatia, Poland, Sweden, Portugal, Netherlands +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

France, Belgium, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Focal Segmental Glomerulosclerosis Fsgs trials by city

Focal Segmental Glomerulosclerosis Fsgs in Toronto Focal Segmental Glomerulosclerosis Fsgs in Vancouver Focal Segmental Glomerulosclerosis Fsgs in Montreal Focal Segmental Glomerulosclerosis Fsgs in Calgary Focal Segmental Glomerulosclerosis Fsgs in Edmonton Focal Segmental Glomerulosclerosis Fsgs in Ottawa Focal Segmental Glomerulosclerosis Fsgs in Winnipeg Focal Segmental Glomerulosclerosis Fsgs in Quebec City Focal Segmental Glomerulosclerosis Fsgs in Hamilton Focal Segmental Glomerulosclerosis Fsgs in Kitchener Focal Segmental Glomerulosclerosis Fsgs in London Focal Segmental Glomerulosclerosis Fsgs in Halifax Focal Segmental Glomerulosclerosis Fsgs in New York Focal Segmental Glomerulosclerosis Fsgs in Los Angeles Focal Segmental Glomerulosclerosis Fsgs in Chicago Focal Segmental Glomerulosclerosis Fsgs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease